Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AOC1 | P19801 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.38 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9374142 | 0.81 | AOC1 (0.41) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL9374083 | 0.80 | AOC1 (0.40) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL1801743 | 0.79 | HRH3 (0.46) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL890216 | 0.76 | — | — | |
| SCHEMBL11033825 | 0.75 | GAA (0.51) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL1829342 | 0.75 | TP53 (0.42) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL26581877 | 0.75 | HRH3 (0.49) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL12669761 | 0.75 | TP53 (0.51) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL19388576 | 0.73 | HRH3 (0.39) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL1664386 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-19 | — | — | US | disclosed |
| US-10822312-B2 | Substituted quinazoline compounds and methods of use | ARAXES PHARMA LLC (US) | 2020-11-03 | — | — | US | disclosed |
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190127336-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | ARAXES PHARMA, LLC | 2019-05-02 | — | — | US | disclosed |
| US-20180186782-A1 | AMIDE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-8637561-B2 | Linked diimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | TP53 28/4885SMN1; SMN2 1357/4885NPC1 4317/4885 |
| US-20180186782-A1 | AMIDE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | TP53 4458/4885SMN1; SMN2 4650/4885NPC1 1666/4885 |
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, KRAS, HRAS | TP53 1/4885SMN1; SMN2 1460/4885NPC1 2176/4885 |
| US-20190127336-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | NRAS, KRAS, HRAS | TP53 31/4885SMN1; SMN2 2895/4885NPC1 3754/4885 |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | TP53 1613/4885SMN1; SMN2 3298/4885NPC1 106/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | TP53 1514/4885SMN1; SMN2 3515/4885NPC1 273/4885 |
| US-10822312-B2 | Substituted quinazoline compounds and methods of use | NRAS, KRAS, HRAS | TP53 63/4885SMN1; SMN2 2856/4885NPC1 2949/4885 |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | KRAS, NRAS, HRAS | TP53 28/4885SMN1; SMN2 1357/4885NPC1 4317/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | TP53 1348/4885SMN1; SMN2 3511/4885NPC1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.